Advanced Research Projects Agency for Health (ARPA-H) will. be at #jpm2024
Step 1) grok the Heilmeier questions and apply them to your biological challenge of choosing (x)
Step 2) Go see if you can find Renee Wegrzyn or any of her colleagues.
Step 3) Take their feedback, revise, and go at it again - it's a #DBTL loop after all
Step 4 through n) Execute your vision to solve for x
Another great panel with some old friends Shirley BerginRick BrightSteve BrozakJoseph Shonkwiler, MD, MBA on ARPA-H / Solutions to Improve Healthcare here at Biotech Showcase JPMWeek. A few highlights:
"Everything today is a comms issue. Every word you say matters and the way you position yourself matters. If you want everybody to understand what you are doing, then the language you use needs to be accessible..." Shirley Bergin. Beautifully said about how to ensure the public values and supports innovation - I could not agree more.
Rick Bright "You have to stay optimistic... the key here to solving the healthcare crisis is public private partnerships."
#JPM2024#scicomms#innovationforchange
Chris Yates, CEO and co-founder of Abingdon Health plc (AIM:ABDX), presented at the Proactive One2One Investor Conference, detailing the company's impressive growth and future plans. Founded in 2008 and headquartered in York, #AbingdonHealth specialises as a #LateralFlow CRO (Contract Research Organisation) and CDMO (Contract Development and Manufacturing Organisation).
The company, with 83 employees primarily in #York and a secondary site in #Doncaster, primarily generates revenue through its contract service business, accounting for 95% of its income. Additionally, Abingdon Health has diversified into self-test products.
Under Yates' leadership, the company has seen substantial revenue growth, reporting just under £5.5 million in the last 12 months and a cash position of nearly £2 million at 2023's end. The firm's expertise in #LateralFlowTest technology, significantly recognised during the #COVID19 pandemic, positions it well in a market expected to expand considerably over the next decade. Abingdon Health's services encompass the full spectrum of product development, from initial ideas to commercial success, including regulatory and analytical laboratory support.
A key element of Abingdon Health's strategy is its focus on CRO and CDMO services, offering a broad portfolio of customers and a significant pipeline of opportunities. The company's business model, which enables long-term revenue through manufacturing customers, is set to drive future growth. Furthermore, the firm has launched self-test products under the "Abingdon Simply Test" brand and provides end-to-end support for retailers creating their own branded products.
Watch at #Proactive#ProactiveInvestors#AIM#ABDXhttps://ow.ly/2M4s50QrCXl
Over the next three years, Digital Health KC and partners UMKC Innovation Center, BioNexus KC, Pipeline Entrepreneurial Fellowship, and KC Digital Drive will advance early-stage digital health companies with programming to increase understanding of the unique aspects of building healthcare solutions, executing a go-to-market plan, and identifying and providing industry-specific mentors and business acumen support.
Join us at our Build-to-Scale Kick-Off event!
Monday, December 18, 2023
11:00 AM - 12:OO PM
Virtual via Zoom - a recording will be shared after the event
REGISTER NOW ▶ https://lnkd.in/dpCNaEb5
Want to dig into how to actually improve equity in data efforts? Register below for the Data Equity Primer, an introductory workshop that, as We All Count says, paints "a clear picture of the challenging landscape of turning complex human questions into numbers then back into meaning (without totally screwing people over in the process!)."
The Data for Equity Funding Collaborative—a collaboration of bi3, HealthPath and Interact for Health—is sponsoring a free introductory workshop on the core issues facing the equitable and ethical use of data.
The free virtual workshop is February 22 from 1-2:30 p.m. EST.
Sign up: https://lnkd.in/grYb8uZb
The 42nd annual J.P. Morgan Healthcare Conference is underway, and the Syneos Health Corporate Affairs Practice has a few predictions about the stories that will dominate media coverage at this year’s event. Click through to see the five themes that emerged from conversations with newsmakers, dealmakers, CEOs, VCs, scientists, and influential reporters leading up to #JPM2024.
We are closely following the action live at #JPM2024 and will share more media insights coming out of the conference. Stay tuned for more conference coverage from our team.
J.P. Morgan Healthcare Conference has just started, and these are the exciting and very relevant topics that will likely be discussed and elaborated, as predicted by the Syneos Health Corporate Affairs Practice.
#syneoshealth#healthcare
The 42nd annual J.P. Morgan Healthcare Conference is underway, and the Syneos Health Corporate Affairs Practice has a few predictions about the stories that will dominate media coverage at this year’s event. Click through to see the five themes that emerged from conversations with newsmakers, dealmakers, CEOs, VCs, scientists, and influential reporters leading up to #JPM2024.
We are closely following the action live at #JPM2024 and will share more media insights coming out of the conference. Stay tuned for more conference coverage from our team.
As we put DIA 2024 in the rearview window, Alira Health is energized by the insights and open-minded discussions that Clients are willing to have, to learn more about everything from Clinical Trial Strategies advancements to how our Alira Health Digital Platform is advancing everything from simple RWE inquiries to Registries to Hybrid/DCTs. Have you listened to any 3rd party insights - for your very expensive clinical development plans?
It's not news that these past two years have been rough, and the biotech ecosystem has had time to reflect on many different aspects before deciding how to move forward.
If there's one word that describes our recently held 2nd Annual Jefferies Healthcare Breakfast Club - 'Survival or Scale: Time to Hold Firm or Capitalise on the Chaos?', it is "OPTIMISM".
In the words of Charles Conn, and despite the economy feeling tough, he agreed that 'venture capital should no longer hide under the bed' and that the present is the best time to deploy capital in the past 15-20 years.
What do you think after reviewing some of the take-home messages highlighted in the video below?
#investment#venturecapital#biotech#privateequity#lifesciences